A partner with the Firm, Josh represents pharmaceutical, biotechnology, medical technology and healthcare clients. He has been with the Firm his entire legal career beginning in 1993.
Josh focuses his practice on technology transfer and licensing and collaboration transactions, manufacturing and distribution arrangements, venture capital financing, mergers and acquisitions and general corporate representation. He advises Boards of Directors and management teams in a broad range of complex business matters through all stages of their companies' development. He also represents companies and individuals in connection with consulting, executive employment, and similar personal services arrangements.
Josh has employed his licensing and transactional expertise as a member of the Patent Resources Group faculty, teaching Patent Counsel's Vital Role in and Guide to Important Corporate Transactions, and was a co-author of the course book. He is also a contributing editor of Massachusetts Limited Liability Company Forms and Practice Manual, published by Data Trace Publishing Co. (1996) and its annual supplements.
•Josh serves as general outside counsel to Sekisui Diagnostics, LLC. A wholly-owned subsidiary of Sekisui Chemical Co. Ltd., Sekisui Diagnostics resulted from the acquisition of the diagnostics business unit from Genzyme Corporation.
•Josh has represented Genzyme Corporation in connection with a number of significant life sciences transactions, including its first collaboration with a Chinese biotechnology company and the formation of MG Biotherapeutics LLC, a joint venture with Medtronic, Inc.
•Josh has represented EnVivo Pharmaceuticals, Inc., a CNS-focused pharmaceutical company, in many of its licensing transactions, including drug development and commercialization collaborations with pharmaceutical companies located in Germany, Japan and Canada.
•Josh has represented Synageva Biopharma Corp., a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutics for rare diseases, in licensing and technology transfer transactions.
•Josh has represented ChanTest Corporation, a provider of integrated ion channel and GPCR services, cell lines, membranes and reagents, in connection with its services and licensing transactions.
•Josh has represented Stemline Therapeutics, Inc., a biopharmaceutical company focusing on the development of compounds that target cancer stem cells, in licensing, manufacturing and technology transfer transactions.
•Josh represented endoVia Medical Inc., a minimally invasive surgical device and robotics client, in its sale of assets to Hansen Medical, Inc.
•Josh has represented issuers and investors in several private placements of convertible notes and preferred stock involving biotech, medtech, and IT companies.
Before Edwards Wildman
Before beginning his legal career at the Firm, Josh worked as an immigration counselor, representing applicants for political asylum in the United States as well as U.S. citizens filing immigrant visa petitions on behalf of family members. Before that, he used his knowledge of the Russian language leading tour groups to the Soviet Union.
Central and Eastern Europe (CEEMENA)
Mr. Thayer was included in the listing as a Rising Star in the area of Securities & Venture Finance by the Massachusetts Super Lawyers publication.